An observational study in Osteoarthritis (OA), Longevity and Wound Care, sponsored by MuseCell Innovations Pte LTD. Recruiting at 2 sites in 2 countries. Open to participants aged Up to 89 Years. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by MuseCell Innovations Pte LTD · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,029 studies in Osteoarthritis with a site in United States — 116 open to participants now, 175 under way, 14 of them phase 3. Osteoarthritis · United States.
Among the 1,029 studies in Osteoarthritis with a site in United States, this one is the 7th largest by planned enrollment of the 188 observational ones that give a count, is one of 36 that started in 2026, is one of 189 observational ones, reaches primary completion later than 158 of the 174 other live ones, and was the 1,004th registered.
2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
Browse Osteoarthritis studies →116 of the 1,029 studies in Osteoarthritis with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
Margaret L Gourlay, MD, MPH · Sites in United States
Ages 50–64
Columbia University · Sites in United States
Ages 18+
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Sites in United States
Ages 18–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.
This study: Up to 89 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,029 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 64 · Phase 2 155 · Phase 3 143 · Phase 4 74
First in 1977; this study’s year is marked. 36 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 100 across 602 observational studies indexed under Osteoarthritis.
Median enrollment 100 across the 832 interventional studies, 114 across the 188 observational. Of the 759 that completed or were terminated, 338 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
473 of 1,029 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with MuseCell Innovations Pte LTD as lead sponsor.
MuseCell Innovations Pte LTD has 1 study filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
60 of the studies in Osteoarthritis with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06269705Phase 3Pacira Pharmaceuticals, IncZILRETTA in Subjects With Shoulder Osteoarthritis | 2026-12 |
| NCT05992883Phase 3Mayo ClinicNSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis | 2026-12-31 |
| NCT07219771Phase 3Doron Therapeutics Inc.A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P) | 2027-06-30 |
| NCT06917404Phase 3Paradigm Biopharmaceuticals Ltd.A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. | 2027-07 |
| NCT06003101Phase 3Massachusetts General HospitalEffect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies | 2027-08-30 |
Add all 60 to your calendar (.ics) → With an account.
Among the 1,029 studies in Osteoarthritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn about the long-term effects of Dezawa MuseCells to treat various diseases.
The Primary Goal: What is the short-term and long- term outcomes of Dezawa Musecells? Participants treated with Dezawa MuseCells as part of their regular medical care and will answer online survey questions about symptoms and clinical outcomes for 5 years.
Multilineage-Differentiating Stress-Enduring (MUSE) cells represent a unique and promising class of endogenous, non-tumorigenic pluripotent-like stem cells. First identified and characterized by Professor Mari Dezawa and her team in 2010, these cells are a naturally occurring somatic stem cells found in the bone marrow, connective tissues of various adult organs, including adipose tissue and dermis, as well as in the peripheral blood. MUSE cells exhibit a "double-feature" profile, combining the most desirable attributes of both pluripotent stem cells like embryonic stem cells and adult mesenchymal stem cells (MSCs). Crucially, this pluripotent-like capacity is coupled with an intrinsic safety mechanism that prevents tumorigenesis. This combination allows MUSE cells to offer the broad regenerative capabilities of pluripotency without the associated oncogenic risks, a major advantage in clinical translation. A cornerstone of MUSE cell therapy is their remarkable immune privilege, which enables the development of "off-the-shelf" therapies.
MUSE cells carry the unique properties of stress-resilience, pluripotency-like and efficient homing to damaged tissue, only a preparation highly enriched for MUSE cells will deliver the therapeutic benefits attributed to "muse cells. Thus, any MSC preparation with substantially less than \~70 % Muse cells are effectively dominated by non-Muse MSCs; in that context the bulk behavior (multipotent, immunomodulatory, limited differentiation) will reflect the MSC phenotype, not the true Muse phenotype, so calling it "muse cells" would be misleading. Because Muse cells naturally constitute only a small fraction of generic MSC isolates, a preparation labeled "Muse cells" but in reality, largely composed of non-Muse MSCs will lack the key properties demonstrated in preclinical/clinical work. Preclinical and clinical efficacy (homing to damaged tissue, differentiation, repair, functional recovery) has been shown specifically with Dezawa MuseCell® products not with mixed MSC populations.
MuseCell Innovations Pte Ltd (MCI) is the exclusive worldwide licensor for the production, distribution, and commercialization of genuine Dezawa MuseCells®, the only clinically validated pluripotent-like, non-tumorigenic, immune-tolerant stem cell platform derived from the scientific work and intellectual property of Professor Mari Dezawa. These authorized and licensed laboratories follow proprietary, patented methodologies licensed directly from MCI and maintain strict controls for sterility, identity, potency, clean-room processing, documentation, and product traceability. This structure ensures that every Dezawa MuseCells® product regardless of country of delivery meets the highest scientific, ethical, and quality standards established by MCI and validated with ongoing global clinical research. Dezawa MuseCells® require licensed, high-purity (≥70% SSEA-3⁺) enrichment and rigorous manufacturing that cannot be performed cheaply, so any low-cost product is simply unpurified MSCs mislabeled as Muse and cannot deliver true Muse-cell effects and may have potential side effects.
This observational, multi-year patient registry is designed to generate a comprehensive understanding of the short-term and long-term clinical outcomes associated with Dezawa MuseCells® when administered as part of routine medical care for a variety of diseases. The study seeks to characterize therapeutic response trajectories, durability of benefit, patient-reported symptomatic changes, and any safety signals that emerge across a five-year follow-up period. Because participants receive Dezawa MuseCells® outside the context of the study protocol, this registry functions exclusively as a structured outcomes-tracking platform rather than an interventional trial. Enrolled participants will complete scheduled online surveys capturing symptoms, quality of life, functional status, adverse events, and other clinically relevant measures at predefined intervals extending through five years.
To ensure high data fidelity, the registry incorporates a formal quality assurance plan that governs data validation and process control. All submitted patient-reported information undergoes automated data checks to confirm adherence to predefined rules for logical range, internal consistency, and compatibility with related fields. Source data verification procedures allow registry personnel to compare a subset of patient-reported entries to external medical records or clinician documentation to assess representativeness and completeness. A controlled data dictionary defines every variable collected within the registry, including source fields, coding frameworks where appropriate, and any relevant standard ranges to support consistent analysis across timepoints. Standard Operating Procedures (SOPs) guide every operational element-patient recruitment, digital survey workflows, longitudinal data collection schedules, data management practices, adverse event reporting expectations, change-control processes, and statistical programming steps-to ensure uniformity and reproducibility of registry activities across the full duration of the study.
The planned sample size is designed to accrue a sufficient number of participants and participant-years to detect clinically meaningful trends in longitudinal outcomes, while also enabling stratified analyses across disease categories, baseline severity levels, and demographic subgroups. The statistical analysis plan outlines the descriptive and inferential approaches used to evaluate the registry's primary objective-short-term and long-term outcome patterns after Dezawa MuseCell® administration as well as secondary objectives related to symptom evolution, functional recovery, durability of response, and safety characterization. Analytical techniques may include longitudinal mixed-effects models, time-to-event analyses, subgroup comparisons, and pattern-of-missingness evaluations, all aligned with a prespecified statistical framework. Together, these procedures establish a high-quality, rigorously managed registry designed to generate meaningful real-world evidence on the long-term clinical performance of Dezawa MuseCells®.
Patients who have undergone treatment with Dezawa MuseCells
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergoing treatment for orthopaedic conditions
Other: MuseCell Treatment
Patients undergoing treatment for longevity and inflammation
Other: MuseCell Treatment
Patients undergoing treatment to treat wounds
Other: MuseCell Treatment
Patients undergoing treatment for various pain conditions
Other: MuseCell Treatment
Patients undergoing treatment with Dezawa MuseCells
Change in Patient Reported Symptom Severity
Change in condition-specific symptom severity following Dezawa MuseCell® administration.
Time frame: Baseline; 1 month; 3 months; 6 months; 12 months; annually through 5 years.
Incidence of Treatment-Related Adverse Events (AEs)
Occurrence, severity, and relatedness of any reported adverse events following Dezawa MuseCell® exposure
Time frame: Baseline through 5 years
Long-Term Functional Improvement
Evaluation of functional capacity and daily activity performance using validated instruments appropriate to the underlying disease
Time frame: Baseline; 1 month; 3 months; 6 months; 12 months; annually through 5 years.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Jul 2031, 60 months later.
Of 82 industry-sponsored observational studies under Osteoarthritis, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 184. This study's planned 60 months is below that.
Counting every sponsor, half of 228 studies reached it within 57 months; a quarter within 21 and three quarters within 141.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.